Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
Authors' conclusion
CZP was associated with maintained drug concentration and efficacy in patients with RA and high RF
Study context
- Population
- Patients with RA, stratified by baseline RF quartile (≤Q3: ≤204 IU/ml; >Q3: >204 IU/ml)baseline RF data available
- Participants
- 453 vs 454
- Comparison
- Certolizumab pegol vs adalimumab, by baseline RF level
- CZPn = 453
- And adalimumab (ADA)n = 454reference
Methodological detailsphase 4, 104-week, single-blind (double-blind until week 12; investigator-blind thereafter), head-to-head, stratified by baseline RF quartile (≤Q3 or >Q3)
- Phase 4
- 104-week
- Single-blind (double-blind until week 12; investigator-blind thereafter)
- Head-to-head
- Stratified by baseline RF quartile (≤Q3 or >Q3)
Primary result
As reported in the abstract
- From week 12, AUC of ADA concentration lower with RF >204 IU/ml vs RF ≤204 IU/ml
- AUC of CZP concentration similar with RF ≤204 IU/ml and >204 IU/ml
- RF ≤204 IU/ml: DAS28-CRP similar between CZP and ADA through week 104
- RF >204 IU/ml: mean DAS28-CRP lower with CZP vs ADA at week 104
- RF >204 IU/ml: proportion achieving DAS28-CRP low disease activity at week 104 greater with CZP vs ADA
- Post hoc analysis
Original publication
Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford). Published 2 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →